FDA Fast Tracks Polaryx Drug PLX-200 for Rare Pediatric Disease

FDA Grants Fast Track Status on March 17, Boosting Drug's Commercial Prospects

Polaryx Therapeutics (Nasdaq: PLYX) secured a critical regulatory advantage on March 17, 2026, when the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its lead drug candidate, PLX-200. The designation targets the drug's use for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2), a severe pediatric neurodegenerative disorder with significant unmet medical need. This status is designed to expedite the development and review of drugs for life-threatening conditions, potentially shortening the timeline to market access through more frequent FDA engagement and the possibility of a rolling review of its future marketing application.

Receiving Fast Track designation represents an important regulatory milestone as we prepare to initiate the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders.

— Alex Yang, Chair and Chief Executive Officer of Polaryx Therapeutics.

SOTERIA Trial to Target 25% of LSD Patient Market in Q3 2026

The strategic value of PLX-200 extends beyond a single indication. The drug is an orally available formulation of gemfibrozil, a compound already approved by the FDA for other uses, which significantly de-risks its safety profile and may lower development costs. Crucially, PLX-200 can cross the blood-brain barrier, a key attribute for treating neurological diseases like CLN2.

Polaryx is preparing to initiate its SOTERIA Phase 2 basket trial in the third quarter of 2026. This trial will assess PLX-200 not only for CLN2 but also for three other rare conditions: CLN3, Krabbe disease, and Sandhoff disease. Combined, the patient populations for these four lysosomal storage disorders (LSDs) represent an estimated one-quarter of the total LSD market, signaling a much larger commercial opportunity for Polaryx if the trials prove successful.